Figures & data
Table I. Patients’ characteristics at start of first-line therapy.
Table II. Results from multiple logistic regression analyses assessing influence of baseline characteristics at start of first-line therapy on risk for not receiving second-line therapy.
Table III. Results from studies on effect of irinotecan-based second-line chemotherapy in metastatic colorectal cancer patients previously treated with oxaliplatin.
Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229–37 Ulrich-Pur H, Kornek GV, Fiebiger W, Gedlicka C, Raderer M, Lenauer A, et al. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Ann Oncol 2001; 12: 1269–72 Stickel F, Jungert B, Brueckl V, Schirner I, Brueckl WM, Mannlein G, et al. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin. Anti-Cancer Drugs 2003; 14: 745–9 Recchia F, Saggio G, Nuzzo A, Lalli A, Di Lullo L, Cesta A, et al. Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. Br J Can 2004; 91: 1442–6 Mabro M, Louvet C, Andre T, Carola E, Gilles-Amar V, Artru P, et al. Bimonthly leucovorin, infusional 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol 2003; 26: 254–8 Mabro M, Artru P, Andre T, Flesch M, Maindrault-Goebel F, Landi B, et al. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer 2006; 94: 1287–92